Abobotulinumtoxina
Dysport (abobotulinumtoxina) is an unknown pharmaceutical. Abobotulinumtoxina was first approved as Dysport on 2009-04-29. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and hyperhidrosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dysport
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dysport | Biologic Licensing Application | 2024-10-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| genetic skin diseases | — | D012873 | — |
| dystonia | — | D004421 | — |
| fissure in ano | — | D005401 | K60.2 |
| hyperhidrosis | — | D006945 | — |
| strabismus | — | D013285 | H50.2 |
| blepharospasm | — | D001764 | G24.5 |
| muscle rigidity | — | D009127 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
abobotulinumtoxina, Dysport, Ipsen Biopharm Limited | |||
| 2123-07-29 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0586 | Injection, abobotulinumtoxina, 5 units |
Clinical
Clinical Trials
1223 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | — | — | 1 | 1 | 7 | 5 | 18 | 31 |
| Dystonia | D004421 | — | — | 1 | 1 | 6 | 1 | 5 | 13 |
| Torticollis | D014103 | — | F45.8 | — | — | 6 | 1 | 5 | 12 |
| Dystonic disorders | D020821 | — | G24 | 1 | 1 | 6 | 1 | 4 | 12 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 3 | 7 | 10 |
| Syndrome | D013577 | — | — | — | 2 | 1 | 1 | 1 | 5 |
| Headache | D006261 | — | R51 | — | — | — | 1 | — | 1 |
| Post-traumatic headache | D051298 | — | G44.3 | — | — | — | 1 | — | 1 |
| Tremor | D014202 | — | R25.1 | — | — | — | 1 | — | 1 |
| Hemiplegia | D006429 | — | G81.0 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 3 | — | 1 | 5 |
| Cerebral palsy | D002547 | — | G80 | — | 1 | 2 | — | 2 | 5 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | 2 | — | 1 | 4 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 3 | — | — | 4 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | 1 | 2 | — | — | 3 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | 2 | 1 | — | — | 3 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 2 | 1 | — | — | 3 |
| Brain injuries | D001930 | — | S06.9 | — | — | 1 | — | 1 | 2 |
| Sclerosis | D012598 | — | — | — | — | 1 | — | 1 | 2 |
| Urinary incontinence | D014549 | — | R32 | — | — | 2 | — | — | 2 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Facies | D019066 | — | — | 2 | 1 | — | — | — | 2 |
| Blepharospasm | D001764 | — | G24.5 | — | 1 | — | — | 1 | 2 |
| Vulvodynia | D056650 | — | N94.81 | — | 1 | — | — | — | 1 |
| Hallux valgus | D006215 | — | — | — | 1 | — | — | — | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 1 | — | — | — | 1 |
| Tardive dyskinesia | D000071057 | — | G24.01 | 1 | 1 | — | — | — | 1 |
| Fissure in ano | D005401 | — | K60.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | — | — | 1 | 1 |
| Tics | D020323 | — | — | — | — | — | — | 1 | 1 |
| Clubfoot | D003025 | — | Q66.0 | — | — | — | — | 1 | 1 |
| Equinus deformity | D004863 | — | — | — | — | — | — | 1 | 1 |
| Talipes | D000070558 | — | Q66.1 | — | — | — | — | 1 | 1 |
| Arm injuries | D001134 | — | — | — | — | — | — | 1 | 1 |
| Caregiver burden | D000084802 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abobotulinumtoxina |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.
|
| Classification | Neurotoxin |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >2VU9:A|BOTULINUM NEUROTOXIN A HEAVY CHAIN
MGSSHHHHHHSSGLVPRGSHMDTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIV
YNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINR
WIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSN
SGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNI
VRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFH
QFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLQ |
Identifiers
| PDB | 2G7P, 2VU9, 2VUA, 3BTA, 3DDA, 3DDB, 3DS9, 3DSE, 3FUO, 3K3Q, 3QIX, 3QIY, 3QIZ, 3QJ0, 3QW5, 3QW6, 3QW7, 3QW8, 3ZUR, 3ZUS, 4EJ5, 4EL4, 4ELC, 4HEV, 4IQP, 4JRA, 4KS6, 4KTX, 4KUF, 4ZJX, 5JLV, 5JMC, 5L21, 5MK6, 5MK7, 5MOY, 5TPB, 5TPC, 5V8P, 5V8R, 5V8U, 5VGV, 5VGX, 6DKK, 6ES1, 6MHJ, 6XCB, 6XCC, 6XCD, 6XCE, 6XCF, 7N18 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108570 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,941 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dysport
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,288 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use